Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment

ConditionSCLC, Extensive Stage

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-75

SponsorYayi He

About this trial

This single-arm phase II study aims to evaluate the efficacy and safety of lomustine combined with anlotinib in patients with extensive-stage small cell lung cancer resistant to second-line and above systemic treatment.

Eligibility criteria

Qualifiers

1: Aged 18-75 years, without gender restriction.

Disqualifiers

1: Previous treatment with lomustine, anlotinib, or other similar anti-angiogenic TKIs.

Trial design

Treatments tested in this trial

Lomustine
Anlotinib

Treatment groups

46 Participants

are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Yayi He

Lead sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Sponsor institution

Source ClinicalTrials.gov